Related Experiment Video
Updated: May 12, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Endovesical treatment as an alternative to BCG for intermediate or high-risk NMI bladder cancer]
Vincenzo Serretta1, Renzo Colombo
1Sezione di Urologia, Dipartimento di Discipline Chirurgiche ed Oncologiche, Università degli Studi di Palermo - Italy.
Abstract:
A shortage of BCG is foreseen till the end of 2013. Which will be the management of intermediate and high-risk NMI-BC if BCG will not be available? In patients harboring high-risk NMI tumors, particularly T1G3 and Tis, the first therapeutic choice is radical cystectomy. Device-assisted therapies, although showing promising results, should be considered only for selected patients. In intermediate risk patients, intravesical chemotherapy remains a legitimate option even if BCG is available. Thus, in a period of BCG shortage, intravesical chemotherapy should be offered, preferably preceded by early instillation, according to the EAU guidelines.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Urologic Endoscopic Procedure: Cystoscopic Examination
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Imaging Studies VI: Voiding Cystourethrography and Cystography
Drugs for Treatment of Ulcerative Colitis in IBD
